Lutetium (177lu) lilotomab satetraxetan

Drug Profile

Lutetium (177lu) lilotomab satetraxetan

Alternative Names: 177Lu lilotomab satetraxetan; 177Lu-DOTA-HH1; 177Lu-Dota-tetulomab; 177Lu-tetraxetan-tetulomab; 177Lutetulomab; Betalutin; Lutetium 177Lu lilotomab satetraxetan

Latest Information Update: 18 Mar 2017

Price : $50

At a glance

  • Originator Nordic Nanovector
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD37 protein inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Follicular lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Diffuse large B cell lymphoma

Most Recent Events

  • 28 Feb 2017 Nordic Nanovector plans to initiate clinical trials for lutetium lilotomab satetraxetan in combination with rituximab in Follicular lymphoma (Second-line therapy) in 2017
  • 28 Feb 2017 Nordic Nanovector plans the pivotal phase II PARADIGME trial for Follicular lymphoma in the second half of 2017
  • 28 Feb 2017 Nordic Nanovector plans to initiate clinical trials in Follicular lymphoma (First-line therapy) in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top